Back to results
US 9,540,431 B2Granted
Inhibitors of the CD95 signaling pathway for treatment of MDS
AssigneeApogenix AG
InventorsHarald Fricke, Michaela Fontenay, Claudia Kunz
Life of this patent
Estimating the term…
Abstract
The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
Claims8
A method for treating myelodysplastic syndrome (MDS) in a patient, comprising the step of administering a fusion protein APG101 comprising an extracellular CD95R domain having the amino acid sequence 26-172 of SEQ ID NO:
- 1 and a human Fc domain having the amino acid sequence 172-400 of SEQ ID NO:
- 1 to a patient in need thereof, wherein the MDS is selected from the IPSS low-risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup, and the fusion protein binds to CD95 ligand (CD95L) and inhibits CD95 signalling pathway.
Dependencies are inferred from the claim text.